Here are the top 5 biosimilars articles for the week of June 25.
Transcript
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of June 25.
Number 5: A study presented at the annual European Congress of Rheumatology found that 80% of 80 patients with rheumatic disease were willing to switch to biosimilar etanercept, and switching did not affect efficacy.
Number 4: During the American Conference Institute’s Summit on Biosimilars, experts from BIO and PhRMA provided an overview of recent policy and legislative updates in biosimilars.
Number 3: Last week, the FDA withdrew a draft guidance document on statistical approaches to evaluate analytical similarity of biosimilars after the consideration of public comments.
Number 2: A recent study has found that disease activity assessment guidelines for patients with rheumatoid arthritis have not been well evaluated in the United States.
Number 1: The American Medical Association has announced that after analyzing the proposed $69 billion dollar merger between pharmacy benefit manager CVS Health and insurer Aetna, the organization is calling for regulators to block the transaction.
To read all of these articles and more, visit centerforbiosimilars.com.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.